Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis

US8796253B2 · kind B2 · utility

Assignee

• Bayer Intellectual Property GmbH · DE

Inventors

• Stephen Boyer · Fairfield, US
• Michael Härter · Wixom, US
• Philip Wickens · Wallingford, US
• Manoj Patel · Berlin, US
• Ellalahewage Sathyajith Kumarasinghe · Harvard, US
• Ajay Kumar Bhargava · Woodbridge, US
• Karl-Heinz Thierauch · Berlin, DE
• Hartmut Beck · Wuppertal, DE
• Susanne Greschat · Goldkronach, DE
• Peter Ellinghaus · Melle, DE
• Patrick Paulus · Frankfurt am Main, DE
• Holger Hess-Stumpp · Berlin, DE

Key dates

• Filing date: May 8, 2008
• Grant date: Aug 5, 2014
• Expiry date: Jan 31, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D491/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates to novel heteroaryl substituted pyrazole compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients or therapeutic measures.